IBEX 35
10.943,70 -7,80 (-0,07%) Euro Stoxx 50
4.894,02 -8,58 (-0,18%) Dólar/Euro
1,0716 +0,0007 (+0,06%) Petróleo Brent
86,48 +0,09 (+0,10%) Oro
2.336,90 +0,30 (+0,01%) Bitcoin EUR
57.345,96 +549,98 (+0,97%)
Algernon Pharmaceuticals Inc. (AGNPF)
Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
Canada
604-398-4175
https://algernonpharmaceuticals.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Christopher J. Moreau | CEO & Director | 397,39k | N/A | 1965 |
| Mr. James F. Kinley C.A., C.P.A. | Chief Financial Officer | 211,8k | N/A | 1978 |
| Dr. Christopher Bryan Ph.D. | Vice President of Research & Operations | 219,1k | N/A | 1983 |
Descripción
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Gobierno corporativo
El ISS Governance QualityScore de Algernon Pharmaceuticals Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
